Pfizer inks $25M research deal

Continuing the hot trend of biopharma companies partnering with research institutions, Pfizer has signed a $25 million, five-year deal with St. Louis-based Washington University. The move extends a previous relationship between the two that stretches back to 1982. As part of the deal, Washington University and Pfizer researchers will identify, design and execute projects focused on immuno-inflammatory disorders such as arthritis, asthma and diabetes. In addition, a fellowship program will allow students and post-docs to experience corporate life.

"This innovative model of partnership intimately links the scientific talent of Washington University with the extraordinary expertise of a pharmaceutical company like Pfizer," said Washington University Chancellor Mark Wrighton. "We believe it will serve as a new paradigm for other academic-industry collaborations." Recently, Pfizer also signed a large research pact with the Scripps Research Institute, and other drug developers have followed suit.

- here's the release on the deal
- see this article for more

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.